Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Inhibition of CDK Activity

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective characterization of clonal hematopoiesis and its clinical associations in elderly patients.

Scientific reports·2025

Same author

An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in Brazil.

Transplantation and cellular therapy·2024

Same author

Molecular taxonomy of myelodysplastic syndromes and its clinical implications.

Blood·2024

Same author

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Blood·2024

Same author

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

NEJM evidence·2024

Same author

Molecular Characterization of a First-in-Human Clinical Response to Nimesulide in Acute Myeloid Leukemia.

Frontiers in oncology·2022

Search research articles

Related Experiment Video

Updated: May 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

JAK2 inhibitors: are they the solution?

Fabio P S Santos¹, Srdan Verstovsek

¹Hematology Program, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Clinical Lymphoma, Myeloma & Leukemia

|November 1, 2011

Summary

This summary is machine-generated.

Targeted JAK2 inhibitors offer new hope for Philadelphia-negative myeloproliferative neoplasms (MPNs). While not curative, these drugs effectively reduce disease burden and symptoms in MPN patients, irrespective of mutation status.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Experiment Videos

Last Updated: May 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) historically had limited treatment options.
The discovery of the JAK2V617F mutation ushered in an era of targeted therapies.
Hydroxyurea, interferon, and chemotherapy were standard treatments for MPNs.

Purpose of the Study:

To review recent data on JAK2 inhibitors for managing Ph-negative MPNs.
To assess the efficacy and limitations of JAK2 inhibitors in myelofibrosis, polycythemia vera, and essential thrombocythemia.
To highlight the ongoing development and clinical trials of novel JAK2 inhibitors.

Main Methods:

Review of recent clinical trial data for JAK2 inhibitors in Ph-negative MPNs.
Analysis of treatment outcomes, including splenomegaly reduction and symptom improvement.
Evaluation of JAK2 inhibitor efficacy across different mutation statuses.

Main Results:

JAK2 inhibitors show potential in reducing disease burden and improving systemic symptoms in MPNs.
Benefits observed include decreased splenomegaly and alleviation of disease-related symptoms.
Efficacy of JAK2 inhibitors is consistent in patients with and without the JAK2V617F mutation.
Current JAK2 inhibitors do not eradicate the malignant clone.

Conclusions:

JAK2 inhibitors represent a significant advancement in treating Ph-negative MPNs.
Further understanding of MPN pathophysiology is crucial for developing curative therapies.
Ongoing clinical trials are exploring new JAK2 inhibitors for various MPNs, including myelofibrosis, polycythemia vera, and essential thrombocythemia.